Physician profile
Ryane M Passno
NPI 1407239478
$4,196.40
in general payments reported to CMS, 2019-2025
27 companies · $1,359 in 2025
The $1,359 reported for 2025 was more than what 89% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $333 · 2022: $425 · 2023: $797 · 2024: $1,282 · 2025: $1,359.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,379 · Education: $60.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,379.16 |
| Education | $60.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,128.28 | 2022-2025 | Farxiga, Airsupra, Fasenra |
| Abbvie INC. | $518.81 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $339.95 | 2022-2025 | Jardiance |
| Novo Nordisk INC | $276.82 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $265.79 | 2021-2025 | Evenity, Prolia |
| Lilly USA, LLC | $255.43 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $213.20 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $201.00 | 2023-2025 | |
| Exact Sciences Corporation | $130.02 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $124.22 | 2021-2024 | Eliquis, Camzyos |
| Astellas Pharma US INC | $123.42 | 2023-2024 | Veozah |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $118.56 | 2022-2025 | Caplyta |
| Gilead Sciences, INC. | $64.08 | 2021-2025 | |
| Insulet Corporation | $63.19 | 2023 | Omnipod |
| Biohaven Pharmaceutical Holding Company LTD. | $61.45 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $51.90 | 2023 | |
| Abbott Laboratories | $40.66 | 2023-2025 | Freestyle Libre 3 |
| Nestle Healthcare Nutrition INC. | $40.31 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $28.40 | 2023 | Quviviq |
| Sanofi-Aventis U.S. LLC | $26.24 | 2021 | |
| Dexcom, INC. | $22.93 | 2023 | Dexcom G6 Transmitter |
| Ironshore Pharmaceuticals INC. | $21.31 | 2022 | |
| Axsome Therapeutics, INC. | $19.90 | 2023 | Auvelity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.52 | 2021 | |
| Alkermes, INC. | $14.12 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $13.70 | 2023 | Austedo |
| Mylan Specialty L.P. | $13.19 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryane Passno listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.